Bicara Therapeutics reports preliminary Phase 1b data showing deep, durable responses and a tolerable safety profile for 2000mg Q2W ficerafusp alfa plus pembrolizumab in 1L HPV-negative head and neck cancer and plans to develop a loading and every-three-week maintenance dosing regimen.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.